Sequencing antiretroviral drugs

AIDS

Volumn 15, Issue 5, 2001, Pages 547-551

  Soriano, V ^a  

^a NONE   (Spain)

Author keywords

Antiretroviral therapy; Drug resistance; Sequencing; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; ENZYME INHIBITION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NEVIRAPINE; NUCLEOSIDES; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS;

EID: 0035970666     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200103300-00002     Document Type: Review

References (58)

1. HIV-RNA and CD4 cell count response to PI therapy in an urban AIDS clinic: Response to both initial and salvage therapy
2. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
3. Strategies for long-term success in the treatment of HIV infection
4. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy regimen in a cohort of antiretroviral naïve patients
5. Virological failure and adherence to antiretroviral therapy in HIV-infected patients
6. Antiretroviral therapy in patients with suboptimal virologic suppression
7. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
8. HIV-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
9. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society - USA Panel
10. Introduction of drug resistance testing in clinical practice
11. Clinical utility of testing HIV for drug resistance
12. Mutations conferring resistance to zidovudine disminish the antiviral effect of stavudine plus didanosine
13. Second Spanish Consensus on the use of drug resistance testing in clinical practice (Madrid, March 2000)
14. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
15. Replicative fitness of protease inhibitor-resistant mutants of HIV-1
16. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
17. Correlation between HIV genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
18. Treatment with indinavir, nevirapine, stavudine, and 3TC following therapy with an amprenavir-containing regimen
19. Genotypic correlates of reduced in vitro susceptibility to ABT-378 in HIV isolates from patients failing protease inhibitor therapy
20. Site-directed mutagenesis and in vitro drug selection studies have failed to reveal a consistent genotypic resistance pattern for tipranavir
21. HIV type 1 selected in patients failing efavirenz combination therapy
22. Nevirapine resistance mutations of HIV type 1 selected during therapy
23. The presence or absence of zidovudine in a nevirapine-containing antiretroviral regimen determines which of two nevirapine-limiting mutations occurs on virologic failure
24. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
25. Can early failure with nevirapine be rescued with efavirenz?
26. HIV-1 isolates that exhibit dose-dependent NNRTI stimulation of RT activity and viral replication
27. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
28. Emergence of ZDV and multidrug resistance in the HIV-1 RT gene in therapy naive patients receiving d4T plus ddI combination therapy
29. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with ddI and d4T in combination
30. Development of zidovudine resistance mutations in patients receiving prolonged ddI monotherapy
31. HIV-1 RT genotype and drug susceptibility changes in infected individuals receiving ddI monotherapy for 1-2 years
32. The power of viral genomics: The example of antiretroviral drug resistance of HIV-1
33. Establishment of biologically relevant cutoffs for HIV drug resistance testing
34. A unique molecular mechanism of resistance to multiple dieoxynucleosides provided by MDR mutations and insertions/deletions in the HIV-1 RT gene
35. Biochemical mechanism of HIV-1 RT resistance to stavudine
36. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 RT in the mechanism of AZT resistance
37. Prevalence and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogues
38. Prevalence and genetic heterogeneity of the RT T69S-S-X insertion in pre-treated HIV-infected patients
39. Phenotypic NRTI resistance profiles in different rearrangements patterns of HIV-1 RT
40. The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with HIV
41. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: Selection of thymidine analog regimen therapy (START I)
42. Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential
43. Decreased processivity of HIV-1 RT containing ddI-selected mutations Leu74Val: A comparative analysis of RT variants Leu74Val and 3TC-selected Met184Val
44. Transmission and prevalence of HIV resistance among treatment-naive subjects
45. Transmission of antiretroviral-resistant HIV-1 variants
46. HIV-1 drug resistance in newly infected individuals
47. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
48. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion
49. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
50. Prevalence of genotypic and phenotypic resistance to antiretroviral drugs in a cohort of therapy-naive HIV-1 infected military personnel
51. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors
52. Primary genotypic and phenotypic resistance to antiretroviral drugs in recent seroconverters in Madrid
53. Prevalence of transmission of HIV-1 drug-resistant mutations in patients with primary HIV-1 infection in Barcelona, Spain
54. Evidence for increasing incidence of transmission of drug resistant HIV-1 in the UK
55. Factors influencing decreased susceptibility to nevirapine in NNRTI-naive patients
56. Decreased susceptibility to NNRTIs induced by nucleoside analogue resistance mutations in the context of RT polymorphisms
57. Putting the brakes on drug approval: Adefovir
58. HIV-1 expressing the lamivudine-associated M184V mutation in RT shows increased susceptibility to adefovir and decreased replication capability in vitro